Abstract: Derivatives of belactosin and their synthesis are disclosed. In certain embodiments, compounds of the present invention exhibit anti-cancer, antiviral, antibiotic, and/or auto-immune therapeutic abilities. In general, methods of synthesis disclosed herein allow for introduction of a variety of substituents at numerous positions as well as the facile introduction of a beta-lactone ring moiety. The synthetic steps comprise, in preferred embodiments, a tandem Mukaiyama aldol lactonization reaction. Data demonstrating the utility of some of the derivatives as proteasome inhibitors is also disclosed.

Abstract: A method for calibration of RF paths of a frequency hopping adaptive base transceiver station is provided. The method of calibration calibrates a wireless cellular telecommunication system with a frequency hopping adaptive base transceiver station including an adaptive antenna array with two or more RF traffic transceiver apparatus chains. The wireless cellular telecommunication system communicates with mobile units on a frequencies defined by a hop list. The method of calibration includes the step of periodically interrupting a frequency hopping process of the frequency hopping adaptive base transceiver station while calls are in progress. The method of calibration further includes the step of calibrating an antenna transmit path for a RF traffic transceiver apparatus chain at a frequency selected to include one or more frequencies in the hop list to determine a set of weighting parameters for the antenna transmit path at the one or more frequencies.

Abstract: We have identified a new variant of ileal bile acid binding protein (IBABP), designated IBABP-L, which is a biomarker for colorectal cancer. The transcript for IBABP-L arises from an alternative start site and includes three exons that are absent in IBABP. IBABP-L also shares part of a fourth exon with IBABP. The protein encoded by IBABP-L contains a deduced 49 residue N-terminal sequence that is not found in the IBABP protein. The present invention provides methods for diagnosing colorectal cancer and other compositions and methods based on this discovery.

Abstract: Method for transferring service for a mobile station call signal from a first base transceiver station to a second base transceiver station in a wireless mobile telecommunication system, while a call is in progress. The method can include receiving at a base transceiver station an access burst from a mobile station with a call already in progress and requiring service from the base transceiver station. Based on the received access burst, the base transceiver station can electronically steer a beam of an adaptive antenna array of the base transceiver station toward a location of the mobile station.

Abstract: The invention provides isolated MMP-2, MMP-9 and MT1-MMP selective substrate polypeptides or functional peptidomimetics. The selective substrate polypeptides contain the following sequences: MMP-2 selective substrate polypeptides contain SEQ ID NOS:1-27, MMP-9 selective substrate polypeptides contain SEQ ID NOS:28-35, and MT1-MMP selective substrate polypeptide contain SEQ ID NOS:36-40. In addition, the invention provides a method of preferentially directing a moiety to a site of MMP-2 activity by administering to a subject an effective amount of an isolated MMP-2 selective substrate polypeptide containing SEQ ID NOS:45-47 linked to a moiety.

Abstract: The present invention provides for compounds of formula (I)-(XIII), as well as pharmaceutically acceptable salts thereof, metabolites thereof, pro-drugs thereof, and pharmaceutical kits that include such compounds. The present invention also provides for the compounds of formula (I)-(XIII) for use in medical therapy or diagnosis. The present invention also provides for the use of the compounds of formula (I)-(XIII) in treating cancer in mammals (e.g., humans), as well inhibiting tumor cell growth in such mammals. The present invention also provides for methods of inhibiting FAS. The methods include contacting FAS with an effective amount of a compound of formula (I)-(XIII). The present invention also provides for methods of inhibiting the TE domain of the FAS. The methods include contacting the thioesterase TE domain of the FAS with an effective amount of a compound of formula (I)-(XIII).

Abstract: The present invention features methods of treating a cancer in a subject by administering an effective amount of a beta-lactone to the subject. The invention also features methods of inhibiting angiogenesis in a subject by administering an effective amount of an inhibitor of fatty acid synthase to the subject. These methods can be used to treat a variety of cancers and other diseases and conditions. The invention also features methods of identifying beta-lactones and other compounds that can be used in the methods of the invention for the treatment of tumors, inhibition of angiogenesis, and the treatment of diseases and conditions that involve pathological angiogenesis.

Abstract: The present invention features methods of treating a cancer in a subject by administering an effective amount of a beta-lactone to the subject. The invention also features methods of inhibiting angiogenesis in a subject by administering an effective amount of an inhibitor of fatty acid synthase to the subject. These methods can be used to treat a variety of cancers and other diseases and conditions. The invention also features methods of identifying beta-lactones and other compounds that can be used in the methods of the invention for the treatment of tumors, inhibition of angiogenesis, and the treatment of diseases and conditions that involve pathological angiogenesis. The invention also features methods of synthesizing beta-lactones and features novel beta-lactone compounds.

Abstract: The present invention features methods of treating a cancer in a subject by administering an effective amount of a beta-lactone to the subject. The invention also features methods of inhibiting angiogenesis in a subject by administering an effective amount of an inhibitor of fatty acid synthase to the subject. These methods can be used to treat a variety of cancers and other diseases and conditions. The invention also features methods of identifying beta-lactones and other compounds that can be used in the methods of the invention for the treatment of tumors, inhibition of angiogenesis, and the treatment of diseases and conditions that involve pathological angiogenesis. The invention also features methods of synthesizing beta-lactones and features novel beta-lactone compounds.

Abstract: A method for calibration of RF paths of a frequency hopping adaptive base transceiver station is provided. The method of calibration calibrates a wireless cellular telecommunication system with a frequency hopping adaptive base transceiver station including an adaptive antenna array with two or more RF traffic transceiver apparatus chains. The wireless cellular telecommunication system communicates with mobile units on a frequencies defined by a hop list. The method of calibration includes the step of periodically interrupting a frequency hopping process of the frequency hopping adaptive base transceiver station while calls are in progress. The method of calibration further includes the step of calibrating an antenna transmit path for a RF traffic transceiver apparatus chain at a frequency selected to include one or more frequencies in the hop list to determine a set of weighting parameters for the antenna transmit path at the one or more frequencies.

Abstract: A method and model for evaluating transmission ultracapacitor response in a power system. The method includes the steps of implementing a transmission ultracapacitor model into power system simulation software, simulating a desired condition of a power system, and determining a desired output power of a transmission ultracapacitor to define a control setpoint. The method further includes the steps of determining the transmission ultracapacitor limit, such that the desired output power does not exceed the transmission ultracapacitor limit, responding to the condition by adjusting output according to the control setpoint, and using the output in conjunction with other elements in the power system to determine an overall system response.

Abstract: A method for calibration of RF paths of a frequency hopping adaptive base transceiver station is provided. The method of calibration calibrates a wireless cellular telecommunication system with a frequency hopping adaptive base transceiver station including an adaptive antenna array with two or more RF traffic transceiver apparatus chains. The wireless cellular telecommunication system communicates with mobile units on a frequencies defined by a hop list. The method of calibration includes the step of periodically interrupting a frequency hopping process of the frequency hopping adaptive base transceiver station while calls are in progress. The method of calibration further includes the step of calibrating an antenna transmit path for a RF traffic transceiver apparatus chain at a frequency selected to include one or more frequencies in the hop list to determine a set of weighting parameters for the antenna transmit path at the one or more frequencies.

Abstract: The invention provides isolated MMP-2, MMP-9 and MT1-MMP selective substrate polypeptides or functional peptidomimetics. The selective substrate polypeptides contain the following sequences: MMP-2 selective substrate polypeptides contain SEQ ID NOS:1-27, MMP-9 selective substrate polypeptides contain SEQ ID NOS:28-35, and MT1-MMP selective substrate polypeptide contain SEQ ID NOS:36-40. In addition, the invention provides a method of preferentially directing a moiety to a site of MMP-2 activity by administering to a subject an effective amount of an isolated MMP-2 selective substrate polypeptide containing SEQ ID NOS:45-47 linked to a moiety.

Abstract: Proteins specific for prostate epithelial cells, normal or neoplastic, are identified and used for diagnosis, development of antibodies, and for evaluating drugs that react with the neoplastic specific proteins. Affinity based probes are used that react specifically with the active site to provide a measure of the enzyme activity of the cells. Prostate epithelial neoplastic cells can be used in screening candidate drugs for their effect in changing the proteome profile as to the serine-threonine hydrolase enzymes, using the affinity based probes for determining the profile.

Abstract: The present invention provides compounds having the general structure A, or a pharmaceutically acceptable derivatives thereof: wherein R is an alkyl group, and R1 comprises at least one moiety selected from a group consisting of an alkyl, an alkenyl, an aryl, a heterocycle, hydroxyl, ester, amido, aldehyde, and a halogen.

Abstract: We have identified a new variant of ileal bile acid binding protein (IBABP), designated IBABP-L, which is a biomarker for colorectal cancer. The transcript for IBABP-L arises from an alternative start site and includes three exons that are absent in IBABP. IBABP-L also shares part of a fourth exon with IBABP. The protein encoded by IBABP-L contains a deduced 49 residue N-terminal sequence that is not found in the IBABP protein. The present invention provides, for example, compositions and methods for diagnosing and treating colorectal cancer.

Abstract: Derivatives of belactosin and their synthesis are disclosed. In certain embodiments, compounds of the present invention exhibit anti-cancer, antiviral, antibiotic, and/or auto-immune therapeutic abilities. In general, methods of synthesis disclosed herein allow for introduction of a variety of substituents at numerous positions as well as the facile introduction of a beta-lactone ring moiety. The synthetic steps comprise, in preferred embodiments, a tandem Mukaiyama aldol lactonization reaction. Data demonstrating the utility of some of the derivatives as proteasome inhibitors is also disclosed.

Abstract: We have identified a new variant of ileal bile acid binding protein (IBABP), designated IBABP-L, which is a biomarker for colorectal cancer. The transcript for IBABP-L arises from an alternative start site and includes three exons that are absent in IBABP. IBABP-L also shares part of a fourth exon with IBABP. The protein encoded by IBABP-L contains a deduced 49 residue N-terminal sequence that is not found in the IBABP protein. The present invention provides methods for diagnosing colorectal cancer and other compositions and methods based on this discovery.

Abstract: The invention provides isolated MMP-2, MMP-9 and MT1-MMP selective substrate polypeptides or functional peptidomimetics. The selective substrate polypeptides contain the following sequences: MMP-2 selective substrate polypeptides contain SEQ ID NOS:1-27, MMP-9 selective substrate polypeptides contain SEQ ID NOS:28-35, and MT1-MMP selective substrate polypeptide contain SEQ ID NOS:36-40. In addition, the invention provides a method of preferentially directing a moiety to a site of MMP-2 activity by administering to a subject an effective amount of an isolated MMP-2 selective substrate polypeptide containing SEQ ID NOS:45-47 linked to a moiety.

Abstract: A spectrally efficient wireless communication system that includes a plurality of base stations communicating indirectly with a plurality of wireless communications devices through a plurality of repeaters. The method can generally comprise communicating indirectly between a first base station and a wireless communication device using a first repeater and a first RF backhaul link. A control processor associated with the first base station can control a first smart antenna system. The system selectively configures the first smart antenna system to spatially isolate communications on the first RF backhaul from communications on a second RF backhaul of a second repeater.